Apretude

Generic name: Cabotegravir
Dosage form: extended-release injectable suspension for intramuscular use
Drug class: Integrase strand transfer inhibitor

Usage of Apretude

Apretude is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg).

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

It is not known if this medicine is safe and effective in children younger than 12 years of age or weighing less than 77 pounds (less than 35 kg).

Apretude side effects

Apretude may cause serious side effects including:

  • Allergic reactions. Call your healthcare provider right away if you develop a rash with Apretude. Stop receiving Apretude and get medical help right away if you develop a rash with any of the following signs or symptoms:
  • fever
  • generally ill feeling
  • tiredness
  • muscle or joint aches
  • trouble breathing
  • blisters or sores in mouth
  • blisters
  • redness or swelling of the eyes
  • swelling of the mouth, face, lips, or tongue
  • Liver problems. Liver problems have happened in people with or without a history of liver problems or other risk factors. Your healthcare provider may do blood tests to check your liver function.

    • Call your healthcare provider right away if you develop any of the following signs or symptoms of liver problems:

  • your skin or the white part of your eyes turns yellow (jaundice)
  • dark or “tea-colored” urine
  • light-colored stools (bowel movements)
  • nausea or vomiting
  • loss of appetite
  • pain, aching, or tenderness on the right side of your stomach area
  • itching
  • Depression or mood changes. Call your healthcare provider or get medical help right away if you have any of the following symptoms:
  • feeling sad or hopeless
  • feeling anxious or restless
  • have thoughts of hurting yourself (suicide) or have tried to hurt yourself

    • The most common side effects include:

  • pain, tenderness, hardened mass or lump, swelling, bruising, redness, itching, warmth, loss of sensation at the injection site, abscess, and discoloration
  • diarrhea
  • headache
  • fever
  • tiredness
  • sleep problems
  • nausea
  • dizziness
  • passing gas
  • stomach pain
  • vomiting
  • muscle pain
  • rash
  • loss of appetite
  • drowsiness
  • back pain
  • upper respiratory infection

    • These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800 FDA1088.

    Before taking Apretude

    You should not receive Apretude if you:

  • already have HIV-1 infection. If you are HIV-1 positive, you will need to take other medicines to treat HIV-1. Apretude is not approved for treatment of HIV-1.
  • do not know your HIV-1 infection status. You may already be HIV-1 positive. You need to take other medicines to treat HIV-1. Apretude can only help reduce your risk of getting HIV-1 infection before you are infected.
  • are allergic to cabotegravir

    • Relate drugs

    How to use Apretude

    Usual Adult Dose for HIV-1 PrEP

    - Initiate Apretude with a single 600-mg (3-mL) injection given 1 month apart for 2 consecutive months on the last day of an oral lead-in if used or within 3 days and continue with the injections every 2 months thereafter.

    - Use: at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating Apretude (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.

    Warnings

    Important information for people who receive Apretude to help reduce their risk of getting human immunodeficiency virus-1 (HIV-1) infection, also called pre exposure prophylaxis or “PrEP”:

    Before receiving Apretude to reduce your risk of getting HIV-1:

  • You must be HIV-1 negative to start Apretude. You must get tested to make sure that you do not already have HIV-1 infection.
  • Do not receive Apretude for HIV-1 PrEP unless you are confirmed to be HIV-1 negative.
  • Some HIV-1 tests can miss HIV-1 infection in a person who has recently become infected. If you have flu-like symptoms, you could have recently become infected with HIV-1. Tell your healthcare provider if you had a flu-like illness within the last month before starting Apretude or at any time while receiving Apretude. Symptoms of new HIV-1 infection include:
  • tiredness
  • joint or muscle aches
  • sore throat
  • rash
  • enlarged lymph nodes in the neck or groin
  • fever
  • headache
  • vomiting or diarrhea
  • night sweats

    • While you are receiving Apretude for HIV-1 PrEP:

  • Apretude does not prevent other sexually transmitted infections. Practice safer sex by using a latex or polyurethane condom to reduce the risk of getting sexually transmitted infections.
  • You must stay HIV-1 negative to keep receiving Apretude for HIV-1 PrEP.
  • Know your HIV-1 status and the HIV-1 status of your partners.
  • Ask your partners with HIV-1 if they are taking anti-HIV-1 medicines and have an undetectable viral load. An undetectable viral load is when the amount of virus in the blood is too low to be measured in a lab test. To maintain an undetectable viral load, your partners must keep taking HIV-1 medicine as prescribed. Your risk of getting HIV-1 is lower if your partners with HIV-1 are taking effective treatment.
  • Get tested for HIV-1 with each Apretude injection or when your healthcare provider tells you. You should not miss any HIV-1 tests. If you become HIV-1 infected and continue receiving Apretude because you do not know you are HIV-1 infected, the HIV-1 infection may become harder to treat.
  • Get tested for other sexually transmitted infections such as syphilis, chlamydia, and gonorrhea. These infections make it easier for HIV-1 to infect you.
  • If you think you were exposed to HIV-1, tell your healthcare provider right away. They may want to do more tests to be sure you are still HIV-1 negative.
  • Get information and support to help reduce sexual risk behaviors.
  • Do not miss any injections of Apretude. Missing injections increases your risk of getting HIV-1 infection.
  • If you do become HIV-1 positive, you will need to take other medicines to treat HIV-1. Apretude is not approved for treatment of HIV-1.

    • If you have HIV-1 and receive only Apretude, over time your HIV-1 may become harder to treat.

    What other drugs will affect Apretude

    Tell your healthcare provider about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements. Some medicines may interact with Apretude. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

    You can ask your healthcare provider or pharmacist for a list of medicines that interact with Apretude.

    Do not receive Apretude if you are taking any of the following medicines:

  • carbamazepine
  • oxcarbazepine
  • phenobarbital
  • phenytoin
  • rifampin
  • rifapentine

    • Do not start a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to receive Apretude with other medicines.

    Popular FAQ

    Apretude (cabotegravir extended-release injection) is a long-acting injection for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Apretude is an integrase strand transfer inhibitor (INSTI) and works by preventing viral DNA from entering the genetic material of human immune cells (T-cells).

    On December 20, 2021, the FDA approved Apretude (cabotegravir extended-release injection), a long acting injection used for HIV-1 pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (35 kg). Check with your doctor about Apretude availability.

    Apretude (cabotegravir extended-release injection), a long-acting injection for HIV PrEP, is made by the pharmaceutical company ViiV Healthcare. In the U.S., ViiV Healthcare can be reached online or at 1-877-844-8872.

    Apretude is probably paid for by your insurance if you have coverage. Based on your medical plan, you might have to pay for a portion of the cost or you may have a $0 copay. The manufacturer, ViiV Healthcare, may offer financial assistance to eligible patients by calling 1-844-588-3288, M-F, 8AM - 11PM (ET).

    Apretude (cabotegravir) extended-release injection is a long-acting pre-exposure prophylaxis (PrEP) prescription medicine used to prevent HIV infection in people at risk for sexually-acquired HIV exposure. Cabenuva (cabotegravir and rilpivirine) is also a long-acting injection but is used to treat (not prevent) HIV-1 infection. Continue reading

    Apretude (cabotegravir extended-release injection) is a long-acting injection for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Apretude is an integrase strand transfer inhibitor (INSTI) and works by preventing viral DNA from entering the genetic material of human immune cells (T-cells).

    On December 20, 2021, the FDA approved Apretude (cabotegravir extended-release injection), a long acting injection used for HIV-1 pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (35 kg). Check with your doctor about Apretude availability.

    Apretude (cabotegravir extended-release injection), a long-acting injection for HIV PrEP, is made by the pharmaceutical company ViiV Healthcare. In the U.S., ViiV Healthcare can be reached online or at 1-877-844-8872.

    Apretude is probably paid for by your insurance if you have coverage. Based on your medical plan, you might have to pay for a portion of the cost or you may have a $0 copay. The manufacturer, ViiV Healthcare, may offer financial assistance to eligible patients by calling 1-844-588-3288, M-F, 8AM - 11PM (ET).

    Apretude (cabotegravir) extended-release injection is a long-acting pre-exposure prophylaxis (PrEP) prescription medicine used to prevent HIV infection in people at risk for sexually-acquired HIV exposure. Cabenuva (cabotegravir and rilpivirine) is also a long-acting injection but is used to treat (not prevent) HIV-1 infection. Continue reading

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords